Financial Performance - For the quarter ended March 2025, Live Nation reported revenue of $3.38 billion, down 11% year-over-year, and EPS of -$0.32 compared to -$0.53 in the same quarter last year [1] - The reported revenue was a surprise of -2.89% compared to the Zacks Consensus Estimate of $3.48 billion, while the EPS surprise was +5.88% against the consensus estimate of -$0.34 [1] Key Metrics - Estimated attendance for concerts totaled 22.31 million, below the average estimate of 23.37 million from five analysts [4] - Total fee-bearing tickets sold were 77.49 million, compared to the average estimate of 79.59 million [4] - Revenue from concerts was $2.48 billion, slightly below the estimated $2.51 billion, representing a year-over-year decline of -13.7% [4] - Revenue from sponsorship and advertising was $216.10 million, slightly below the estimate of $216.47 million, with a year-over-year increase of +2.3% [4] - Revenue from ticketing was $694.70 million, compared to the average estimate of $773.21 million, reflecting a year-over-year change of -3.9% [4] Stock Performance - Shares of Live Nation have returned -1.6% over the past month, while the Zacks S&P 500 composite changed by -0.7% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Glaukos reported $106.66 million in revenue for Q1 2025, a 24.6% year-over-year increase, with an EPS of -$0.22 compared to -$0.70 a year ago, exceeding the Zacks Consensus Estimate of $102.72 million by 3.84% [1] - The company achieved an EPS surprise of 33.33%, with the consensus EPS estimate being -$0.33 [1] Revenue Breakdown - U.S. revenues reached $75.07 million, surpassing the average estimate of $71.54 million, reflecting a 30.1% year-over-year increase [4] - International revenues totaled $31.59 million, slightly above the average estimate of $31.35 million, marking a 13.1% year-over-year increase [4] - Corneal Health revenues in the international market were $2.59 million, below the average estimate of $2.78 million, showing a decline of 4.1% year-over-year [4] - U.S. Corneal Health revenues were $15.94 million, exceeding the average estimate of $15.50 million, with a 1.5% year-over-year increase [4] - International Glaucoma revenues amounted to $29.01 million, surpassing the average estimate of $28.57 million, reflecting a 14.9% year-over-year increase [4] - U.S. Glaucoma revenues reached $59.13 million, exceeding the average estimate of $56.03 million, with a significant 40.8% year-over-year increase [4] - Total Corneal Health revenues were $18.53 million, slightly above the average estimate of $18.28 million, representing a 0.7% year-over-year increase [4] - Total Glaucoma revenues were $88.14 million, exceeding the average estimate of $84.60 million, reflecting a 31.1% year-over-year increase [4] Stock Performance - Glaukos shares have returned -5.8% over the past month, compared to the Zacks S&P 500 composite's -0.7% change, with a current Zacks Rank of 3 (Hold) indicating potential performance in line with the broader market [3]

Financial Performance - For the quarter ended March 2025, Sprouts Farmers (SFM) reported revenue of $2.24 billion, an increase of 18.7% year-over-year [1] - EPS for the quarter was $1.81, up from $1.12 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $2.2 billion, resulting in a surprise of +1.88% [1] - The company delivered an EPS surprise of +17.53%, with the consensus EPS estimate being $1.54 [1] Key Metrics - Comparable store sales growth was 11.7%, surpassing the average estimate of 10.7% based on four analysts [4] - The number of stores at the end of the period was 443, slightly below the four-analyst average estimate of 444 [4] - Three new stores were opened, compared to an average estimate of four by three analysts [4] - The number of stores at the beginning of the period was 440, matching the two-analyst average estimate [4] Stock Performance - Shares of Sprouts Farmers have returned +11% over the past month, while the Zacks S&P 500 composite experienced a -0.2% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential outperformance against the broader market in the near term [3]

Core Insights - Ionis Pharmaceuticals reported revenue of $132 million for the quarter ended March 2025, reflecting a year-over-year increase of 10.9% and surpassing the Zacks Consensus Estimate of $120.16 million by 9.86% [1] - The company's EPS was -$0.75, an improvement from -$0.98 in the same quarter last year, with an EPS surprise of 32.43% against a consensus estimate of -$1.11 [1] Revenue Breakdown - Commercial revenue from SPINRAZA royalties was $48 million, exceeding the average estimate of $43.02 million by nine analysts, marking a 26.3% increase year over year [4] - Total commercial revenue reached $76 million, surpassing the average estimate of $66.61 million based on eight analysts, representing a 28.8% year-over-year change [4] - Total research and development revenue was $56 million, compared to the average estimate of $50.44 million [4] - WAINUA royalties generated $9 million, slightly below the average estimate of $9.89 million [4] - Other commercial revenue from TEGSEDI and WAYLIVRA was $6 million, falling short of the average estimate of $6.93 million, indicating a 33.3% decline year over year [4] - Collaborative agreement revenue within research and development was $46 million, exceeding the average estimate of $37.10 million, but reflecting a 6.1% decrease year over year [4] Stock Performance - Ionis Pharmaceuticals' shares have returned +9.4% over the past month, contrasting with a -0.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

For the quarter ended March 2025, Woodward (WWD) reported revenue of $883.63 million, up 5.8% over the same period last year. EPS came in at $1.69, compared to $1.62 in the year-ago quarter.The reported revenue represents a surprise of +6.43% over the Zacks Consensus Estimate of $830.26 million. With the consensus EPS estimate being $1.44, the EPS surprise was +17.36%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...

Alexandria Real Estate Equities (ARE) reported $758.2 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 1.4%. EPS of $2.30 for the same period compares to $0.97 a year ago. View all Key Company Metrics for Alexandria Real Estate Equities here>>> The reported revenue compares to the Zacks Consensus Estimate of $749.53 million, representing a surprise of +1.16%. The company delivered an EPS surprise of +0.88%, with the consensus EPS estimate being $2.28. Shares of A ...

Welltower (WELL) reported $2.42 billion in revenue for the quarter ended March 2025, representing a year- over-year increase of 30.3%. EPS of $1.20 for the same period compares to $0.22 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $2.37 billion, representing a surprise of +2.12%. The company delivered an EPS surprise of +4.35%, with the consensus EPS estimate being $1.15. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...

View all Key Company Metrics for Domino's Pizza here>>> While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps inve ...

Core Insights - Baker Hughes reported revenue of $6.43 billion for the quarter ended March 2025, a slight year-over-year increase of 0.1% [1] - The company's EPS for the same period was $0.51, up from $0.43 a year ago, exceeding the consensus estimate of $0.47 by 8.51% [1] - Revenue fell short of the Zacks Consensus Estimate of $6.51 billion, resulting in a surprise of -1.31% [1] Financial Performance - Total orders for the quarter were $6.46 billion, slightly above the average estimate of $6.43 billion [4] - Orders in the Industrial & Energy Technology segment were $3.18 billion, exceeding the $3.09 billion estimate [4] - Oilfield Services & Equipment orders were $3.28 billion, below the $3.42 billion estimate [4] Segment Revenue Analysis - Revenue from Oilfield Services & Equipment International was $2.58 billion, a decline of 7.7% year-over-year, and below the $2.62 billion estimate [4] - North America Oilfield Services & Equipment revenue was $922 million, slightly above the $917.32 million estimate, representing a year-over-year decrease of 6.9% [4] - Revenue from Climate Technology Solutions surged to $178 million, a significant increase of 114.5% year-over-year, surpassing the $146.53 million estimate [4] Stock Performance - Baker Hughes shares have declined by 18.5% over the past month, compared to a 5.1% decline in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Core Insights - Raymond James Financial, Inc. reported $3.4 billion in revenue for the quarter ended March 2025, marking a year-over-year increase of 9.1% and an EPS of $2.42 compared to $2.31 a year ago, although it fell short of the Zacks Consensus Estimate of $3.43 billion by -0.72% [1] Financial Performance Metrics - Private Client Group Asset Under Management was $1.48 billion, slightly below the three-analyst average estimate of $1.49 billion [4] - Tier 1 Leverage Ratio stood at 13.3%, exceeding the three-analyst average estimate of 13.1% [4] - Private Client Group assets in Fee-based Accounts totaled $872.80 million, below the average estimate of $880.13 million [4] - Total Capital Ratio was 24.8%, surpassing the two-analyst average estimate of 24.5% [4] - Investment banking revenues were reported at $216 million, a year-over-year increase of 20.7%, but below the average estimate of $255.78 million [4] - Asset management and related administrative fees generated $1.73 billion, reflecting a year-over-year change of 13.8% and exceeding the average estimate of $1.71 billion [4] - Total brokerage revenues reached $580 million, a year-over-year increase of 9.9%, surpassing the average estimate of $562.59 million [4] - Account and service fees were $321 million, down 4.2% year-over-year and below the average estimate of $338.37 million [4] - Interest income was reported at $963 million, a decrease of 8.2% year-over-year, falling short of the average estimate of $993.09 million [4] - Other total revenues were $40 million, showing a year-over-year increase of 29%, slightly below the average estimate of $40.96 million [4] - Principal transactions generated $149 million, a year-over-year increase of 30.7%, exceeding the three-analyst average estimate of $130.55 million [4] - Net interest income was $419 million, a year-over-year increase of 1.5%, but below the average estimate of $513.85 million [4] Stock Performance - Shares of Raymond James Financial have returned -7.5% over the past month, compared to the Zacks S&P 500 composite's -6.6% change, with a Zacks Rank 4 (Sell) indicating potential underperformance in the near term [3]